Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQSTNASDAQ:CHMANASDAQ:CMRXNASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$3.00+2.7%$2.77$2.20▼$5.80$296.61M2.591.48 million shs1.22 million shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsCMRXChimerix$8.54$8.00$0.75▼$8.55$801.09M-0.172.31 million shsN/AXERSXeris Biopharma$4.48-2.0%$4.53$1.72▼$6.07$700.61M1.371.90 million shs1.86 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.82%+3.55%+0.69%-5.19%-13.10%CHMAChiasma0.00%0.00%0.00%0.00%0.00%CMRXChimerix0.00%0.00%+0.35%+107.79%+808.51%XERSXeris Biopharma+3.63%+10.65%-16.76%+24.86%+161.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.6579 of 5 stars3.62.00.00.02.90.00.0CHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/ACMRXChimerix3.0034 of 5 stars1.04.00.04.12.82.50.6XERSXeris Biopharma3.5759 of 5 stars3.41.00.04.21.91.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.14Buy$10.67255.56% UpsideCHMAChiasma 0.00N/AN/AN/ACMRXChimerix 2.00Hold$8.53-0.08% DownsideXERSXeris Biopharma 2.80Moderate Buy$6.1036.16% UpsideCurrent Analyst Ratings BreakdownLatest AQST, XERS, CHMA, and CMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/10/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025AQSTAquestive TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$7.003/7/2025AQSTAquestive TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/7/2025AQSTAquestive TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.003/7/2025XERSXeris BiopharmaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $6.003/7/2025XERSXeris BiopharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.503/7/2025XERSXeris BiopharmaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $4.003/7/2025XERSXeris BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.60 ➝ $8.003/5/2025CMRXChimerixJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$10.00 ➝ $8.503/5/2025CMRXChimerixWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$7.00 ➝ $8.55(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M5.15N/AN/A($1.59) per share-1.89CHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94XERSXeris Biopharma$203.07M3.45N/AN/A($0.05) per share-89.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%5/6/2025 (Estimated)CHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/ACMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%5/7/2025 (Estimated)XERSXeris Biopharma-$62.26M-$0.38N/AN/AN/A-33.69%N/A-17.38%5/8/2025 (Estimated)Latest AQST, XERS, CHMA, and CMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025XERSXeris Biopharma-$0.07N/AN/AN/A$57.61 millionN/A5/7/2025Q1 2025CMRXChimerix-$0.27N/AN/AN/AN/AN/A5/6/2025Q1 2025AQSTAquestive Therapeutics-$0.17N/AN/AN/A$12.23 millionN/A3/21/2025Q4 2024CMRXChimerix-$0.26-$0.25+$0.01-$0.25$0.31 million$0.06 million3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A6.375.91CHMAChiasmaN/A7.917.08CMRXChimerixN/A6.336.33XERSXeris BiopharmaN/A1.791.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%CHMAChiasma61.68%CMRXChimerix45.42%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics7.85%CHMAChiasma8.30%CMRXChimerix13.10%XERSXeris Biopharma4.56%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16098.87 million84.02 millionOptionableCHMAChiasma8557.89 millionN/ANot OptionableCMRXChimerix9093.80 million78.15 millionOptionableXERSXeris Biopharma290156.39 million142.28 millionOptionableAQST, XERS, CHMA, and CMRX HeadlinesRecent News About These CompaniesXeris Biopharma (NASDAQ:XERS) Sees Large Volume Increase - Time to Buy?April 30 at 1:08 PM | marketbeat.comXeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To ProfitApril 26, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 23, 2025 | msn.comJPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 22, 2025 | marketbeat.comRenaissance Technologies LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 21, 2025 | marketbeat.comEAM Investors LLC Buys New Shares in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 20, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 4.9% - Here's What HappenedApril 18, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short InterestApril 18, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Shares Up 4.9% - What's Next?April 17, 2025 | marketbeat.comKennedy Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 16, 2025 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc.April 16, 2025 | marketbeat.comCenterBook Partners LP Sells 2,791,929 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)April 12, 2025 | marketbeat.comXeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's WhyApril 3, 2025 | marketbeat.comXeris Announces Changes to Its Board of DirectorsMarch 28, 2025 | finance.yahoo.comIs Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?March 27, 2025 | msn.comStrength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?March 20, 2025 | zacks.com12 Best Stocks to Invest in for a Stock Market GameMarch 20, 2025 | insidermonkey.comXeris enters a whole new market for one of its main pharma offeringsMarch 20, 2025 | chicagobusiness.comXeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market GameMarch 19, 2025 | insidermonkey.comCalculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)March 18, 2025 | finance.yahoo.comFDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aidMarch 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat2 Healthcare Recession-Resistant Stocks Unaffected by TariffsBy Jea Yu | April 15, 2025View 2 Healthcare Recession-Resistant Stocks Unaffected by TariffsAQST, XERS, CHMA, and CMRX Company DescriptionsAquestive Therapeutics NASDAQ:AQST$3.00 +0.08 (+2.74%) Closing price 04:00 PM EasternExtended Trading$2.98 -0.02 (-0.83%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Chiasma NASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Xeris Biopharma NASDAQ:XERS$4.48 -0.09 (-1.97%) Closing price 04:00 PM EasternExtended Trading$4.47 -0.01 (-0.11%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Crushes Earnings, What’s Next for MSFT Stock? McDonald’s Insiders Sell Shares! Investors Should Do the Opposite Qualcomm's Earnings: 2 Reasons to Buy, 1 to Stay Away Broadcom: Buy, Hold, Sell? AI & Acquistions Paint Strong Picture Hershey Hits the Sweet Spot for Defensive Investors A Bull Case for Adobe Stock Remains Today AMD Stock Signals Strong Buy Ahead of Earnings BigBear.ai: A Short-Squeeze Is Possible, a Sharp Drop Is Likely Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
